Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 12/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823762 | 1.00 | ADRA1A (0.36) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5912788 | 0.98 | ALDH1A1 (0.38) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL16827275 | 0.98 | ALDH1A1 (0.38) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29877044 | 0.98 | ALDH1A1 (0.38) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL24183458 | 0.94 | HTR6 (0.35) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL18427060 | 0.94 | HTR6 (0.35) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28842926 | 0.93 | ALDH1A1 (0.35) | ADRA1AALDH1A1HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL23482908 | 0.89 | HTR6 (0.48) | ADRA1AALDH1A1HTR6LMNAKDM4E | |
| SCHEMBL23507346 | 0.88 | KDM4E (0.32) | KDM4E | |
| SCHEMBL23252499 | 0.88 | KDM4E (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| EP-3083594-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029648-A | Substituted bipiperidinyl derivatives as adrenergic receptor alpha 2C antagonists | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-3044218-A2 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | Board Of Regents Of the University Of Texas System (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| WO-2015091415-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-8283360-B2 | Bicyclic heterocyclic derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | SCHERING PLOUGH CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20060194811-A1 | Pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1595869-A1 | PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ADRA1A 4675/4885ALDH1A1 4595/4885HTR6 3112/4885 |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | ADRA1A 1241/4885ALDH1A1 3111/4885HTR6 1380/4885 |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | ADRA1A 4675/4885ALDH1A1 4595/4885HTR6 3112/4885 |
| US-20060194811-A1 | Pyrimidine derivatives | ADORA3, NR4A1, NR0B1 | ADRA1A 43/4885ALDH1A1 1991/4885HTR6 75/4885 |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | GPR119, GID4, TLR4 | ADRA1A 870/4885ALDH1A1 1161/4885HTR6 350/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | ADRA1A 225/4885ALDH1A1 2836/4885HTR6 403/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | ADRA1A 4675/4885ALDH1A1 4595/4885HTR6 3112/4885 |
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | ADRA1A 3251/4885ALDH1A1 1547/4885HTR6 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.